3P Biopharmaceuticals receives FDA approval
News and updates
Press Releases
Lokon Pharma AB signs an agreement with Biovian
3P Biopharmaceuticals and Buzzard Pharmaceuticals start a cGMP manufacturing collaboration to develop a new treatment to combat solid tumours
Working in biotechnology means working to improve the planet and people’s lives
Tenboron Ltd signs an agreement with Biovian for GMP contract manufacturing of a novel boron carrier for treating solid tumors
Eurocine Vaccines initiates process development of the vaccine candidate against chlamydia
The University of Navarra and the company 3P Biopharmaceuticals will promote research and talent management in technology and the production of new drugs.
Annexin and Biovian have successfully completed ANXV manufacturing
Affibody AB has selected Biovian as a CDMO partner for their novel therapeutic protein candidate, ABY-062.
Eurocine Vaccines has selected Biovian as contract developer for the chlamydia vaccine candidate
3P Biopharmaceuticals and Invizius hope for reducing the cardiovascular complications associated with dialysis
3P Biopharmaceuticals and SpyBiotech enter into a Vaccine cGMP Manufacturing Agreement
Biovian signs an agreement about early-stage development and manufacturing of a COVID-19 vaccine candidate.
Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)
3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research
Biovian’s new facility for Viral Vector GMP manufacturing is completed
